Replies to post #12772 on BioCurex, Inc.(fka BOCX)

[opportunityknocking]

When you read the press release again Dr Moro says he is pretty much ready to commercialize the manual recaf test to generate a revenue stream and it is the automated test that will require more due diligence. The manual test has been extemely proficient for quite some time, but he was concentrating on the automated test so hard that he was forgetting that he can sell the manual test now. This is a class 1 device and will not require the PMA (or am I mistaken)? We need to get this into the hands of all academia so they can see for themselves this wasn't contrived data we were presenting.